UROV Urovant Sciences Ltd.

8.49
-0.56  -6%
Previous Close 9.05
Open 9.75
Price To Book -38.59
Market Cap 257441514
Shares 30,322,911
Volume 161,260
Short Ratio
Av. Daily Volume 43,906

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated in 2019.
hMaxi-K
Overactive bladder (OAB)
Phase 2a initiation of enrolment announced January 3, 2019.
Vibegron
Irritable bowel syndrome (IBS)
Phase 3 trial to be initiated 4Q 2018 or 1Q 2019.
Vibegron
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
Phase 3 data due March 2019.
Vibegron
Overactive bladder (OAB)